Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: BARRY ALLEN who wrote (2897)	7/29/1999 11:09:00 PM
From: BARRY ALLEN	Respond to of 4140

Wednesday July 28, 4:29 am Eastern Time FOCUS-US flu drug approval revives Biota By Sonali Paul MELBOURNE, July 28 (Reuters) - Australian research group Biota Holdings Ltd got a shot in the arm from U.S. approval for sales of its new flu drug Relenza, putting the company potentially on course for its first ever profit this year. Biota's share price recuperated from a bad slump thanks to the nod from the U.S. Food and Drug Administration, reversing most of the hammering the company took last February when an FDA advisory panel voted against recommending Relenza for approval. Its shares closed at A$7.93 (US$5.11) after hitting a high of A$9.10 soon after the opening, the same price Biota was trading at before the knockback last February, which sent the price down to A$4.35. THERE IS HOPE! GO SNRS!